RxDoctor Payments Data

Alan Gowan, DO

Medical Oncology · Temple, TXNPI 1417917105

Payments from drug & device makers

$284,314in general payments, 2019–2025

Across 61 payments — averaging $4660.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$107K
  • AbbVie$68K
  • Jazz Pharmaceuticals Inc.$46K
  • Eli Lilly$37K
  • Pfizer$27K
  • Lilly USA, LLC$28
$800in research payments, 2019–2025

Across 2 payments — averaging $400.19 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$800

What the payments were for

  • Food & beverage$28100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
E.r. Squibb & Sons, L.L.C.7$106,693
AbbVie27$67,724
Jazz Pharmaceuticals Inc.18$46,000
Eli Lilly3$36,676
Pfizer4$27,194
Lilly USA, LLC2$28

How this compares

$284,314 in reported general payments places this provider in the 60th percentile of 495 medical oncology providers in Texas.

See all medical oncology providers in Texas

Medicare billing

Part B allowed, 2024
$124,914
Medicare patients
279
Services billed
1,484

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TagrissoOsimertinib Mesylate62$1,043,236
ErivedgeVismodegib15$215,019
Somatuline DepotLanreotide Acetate14$138,955
EliquisApixaban64$55,058
Lidocaine-PrilocaineLidocaine/Prilocaine67$774
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen32$733
Prochlorperazine Maleate78$683
Levothyroxine Sodium61$520
Gabapentin40$487
Dexamethasone28$398
Ondansetron OdtOndansetron26$370
Triamcinolone Acetonide16$268
Mirtazapine18$214
Potassium Chloride18$167
Citalopram HbrCitalopram Hydrobromide14$141

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$27,194$55,05864 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 495 medical oncology providers in Texas.

Other medical oncology in Temple

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →